Long-term prognosis in patients continuing taking antithrombotics after peptic ulcer bleeding

Table 1 Baseline information between the continuing and discontinuing groups n (%)

Characteristic	Continuing group	Discontinuing group	T/χ2	P value
No. of patients	98	69
Demographic data
Gender (male/%)	68 (69.39)	42 (60.87)	1.307	0.253
Age (mean ± SD)	70.8 ± 11.4	62.4 ± 12.0	4.588	0.000
BMI (kg/m2, mean ± SD)	21.4 ± 4.5	22.0 ± 4.2	0.872	0.385
Complications
Smoking and alcohol abuse	8 (8.2)	15 (21.7)	6.284	0.012
Diabetes	32 (32.7)	15 (21.7)	2.385	0.123
Hypertension	71 (72.4)	56 (81.2)	1.338	0.247
Chronic kidney disease	23 (23.4)	8 (11.6)	3.777	0.052
Chronic obstructive pulmonary disease	10 (10.2)	8 (11.6)	0.081	0.775
Acute cardiovascular disease	65 (66.3)	13 (18.8)	36.681	0.000
Non-antithrombotic drug usage
Aspirin	84 (85.7)	59 (85.5)	0.001	0.970
Forrest classification
I-II	31 (31.6)	28 (40.6)	1.419	0.234
III	67 (68.4)	41 (59.4)	1.419	0.234
Hemoglobin (g/dL)	9.0 ± 2.4	8.6 ± 2.1	1.116	0.266

Table 2 Comparison of various outcomes achieved between the two groups n (%)

	Continuing group	Discontinuing group	χ2	P value
Recurrent ulcer bleeding events	18 (18.4)	4 (5.8)	5.594	0.018
Death or cardiovascular disease	3 (3.1)	15 (21.7)	14.689	0.000

Table 3 COX regression multivariate analysis of risk factors for prognosis

	Recurrent ulcer bleeding events				Death or cardiovascular occurrence
	β	OR	95%CI	P value	β	OR	95%CI	P value
Usage of antithrombotics	1.094	2.986	1.067-8.356	0.015	1.652	5.216	1.035-26.278	0.028

Usage of antithrombotics